Interaction between probiotic lactic acid bacteria and canine enteric pathogens: a risk factor for intestinal Enterococcus faecium colonization?
Selected probiotic lactic acid bacteria (LAB) have been shown to elicit positive health effects particularly in humans. Competitive exclusion of pathogens is one of the most important beneficial health claims of probiotic bacteria. The effect of probiotic LAB on competitive exclusion of pathogens has been demonstrated in humans, chicken and pigs. In this study we evaluated the ability of certain LAB strains (Lactobacillus rhamnosus GG, Bifidobacterium lactis Bb12, Lactobacillus pentosus UK1A, L. pentosus SK2A, Enterococcus faecium M74 and E. faecium SF273) to inhibit the adhesion of selected canine and zoonotic pathogens (Staphylococcus intermedius, Salmonella Typhimurium ATCC 14028, Clostridium perfringens and Campylobacter jejuni) to immobilised mucus isolated from canine jejunal chyme in vitro. Adhesion of C. perfringens was reduced significantly by all tested LAB strains, between 53.7 and 79.1% of the control without LAB, the LAB of canine origin yielding the best reduction. The adhesion of S. Typhimurium and S. intermedius were not significantly altered by any of the LAB included in the study. Both enterococci tested significantly enhanced the adhesion of C. jejuni, to 134.6 and 205.5% of the control without LAB. E. faecium may thus favor the adhesion and colonization of C. jejuni in the dog's intestine, making it a potential carrier and possibly a source for human infection. Enhanced C. jejuni adhesion is a new potential risk factor of enterococci. Our results further emphasize the importance of safety guidelines to be established for the probiotics intended for animal use.
Rinkinen
Minna
M
Faculty of Veterinary Medicine, Department of Clinical Veterinary Sciences, University of Helsinki, P.O. Box 57, Helsinki FIN-00014, Finland. minna.rinkinen@helsinki.fi
Jalava
Katri
K
Westermarck
Elias
E
Salminen
Seppo
S
Ouwehand
Arthur C
AC
D000818:Animals; D001422:Bacterial Adhesion / Q000502:physiology; D016123:Campylobacter jejuni / Q000254:growth & development; D003016:Clostridium perfringens / Q000254:growth & development; D004283:Dog Diseases / Q000382:microbiology* / Q000473:pathology; D004285:Dogs; D016984:Enterococcus faecium / Q000254:growth & development*; D005260:Female; D016908:Gram-Positive Bacterial Infections / Q000382:microbiology / Q000503:physiopathology / Q000662:veterinary*; D066298:In Vitro Techniques; D007410:Intestinal Diseases / Q000382:microbiology / Q000503:physiopathology / Q000662:veterinary*; D007413:Intestinal Mucosa / Q000382:microbiology* / Q000503:physiopathology; D007778:Lactobacillus / Q000378:metabolism*; D008297:Male; D019936:Probiotics / Q000494:pharmacology*; D012486:Salmonella typhimurium / Q000254:growth & development